Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for Patients with Cervical Cancer and Intermediate Pathologic Risk Factors By Ogkologos - September 24, 2025 515 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NRG Oncology/GOG-263/KGOG1008 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Omission of Completion Axillary Lymph Node Dissection Noninferior to More Extensive... April 8, 2024 Qué debo saber sobre la mastectomía con cierre plano después de... January 17, 2024 Worries About Medical Bills May Worsen Health Outcomes After Cancer Diagnosis March 13, 2021 ASCO Annual Meeting 2023: Radiation Therapy May Not Be Needed After... June 6, 2023 Load more HOT NEWS Treating High-Risk Bladder Cancer and Analyzing PSA Screening for Prostate Cancer:... Woman Develops Breast Cancer After Double Mastectomy, Has to Have the... How longer waiting times are impacting teens and young adults Datopotamab Deruxtecan Improves Survival Over Chemotherapy in Patients with Previously Untreated,...
